Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The interleukin-23 pathway is implicated genetically and biologically in the pathogenesis of Crohn's disease. We aimed to assess the efficacy and safety of risankizumab (BI 655066, Boehringer Ingelheim, Ingelheim, Germany), a humanised monoclonal antibody targeting the p19 subunit of interleukin-23, in patients with moderately-to-severely active Crohn's disease.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet

Title: Lancet (London, England)

Publisher: Elsevier BV

ISSN (Electronic): 1474-547X

ISSN (Print): 0140-6736

Publication date (Electronic): Apr 29 2017

Volume: 389

Issue: 10080

Affiliations

[1 ] Western University, Robarts Clinical Trials, London, ON, Canada. Electronic address: brian.feagan@robartsinc.com.

[2 ] IBD Center, University of California San Diego and UC San Diego Health System, San Diego, CA, USA.

[3 ] Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.

[4 ] Hospital Clinic Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.

[5 ] University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.

[6 ] University Hospitals Leuven, Leuven, Belgium.

[7 ] University Hospital CHU Liège, Liège, Belgium.

[8 ] Erasme University Hospital, Brussels, Belgium.

[9 ] Cliniques Universitaires Saint-Luc, Brussels, Belgium.

[10 ] Hannover Medical School, Hannover, Germany.

[11 ] Asan Medical Center, Seoul, South Korea.

[12 ] University of Erlangen-Nürnberg, Erlangen, Germany.

[13 ] Christian-Albrechts-University Kiel, Kiel, Germany.

[14 ] Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA.

[15 ] Boehringer Ingelheim Pharma GmbH, Ingelheim, Germany.

[16 ] Boehringer Ingelheim RCV GmbH, Vienna, Austria.

Article

Publisher Item ID: S0140-6736(17)30570-6

DOI: 10.1016/S0140-6736(17)30570-6

PubMed ID: 28411872

SO-VID: 3eac60a5-a294-4696-9c4e-ffa8f35d073b

History

Data availability:

Comments

Comment on this article

scite_

Cited by 170

See all cited by